Agios Pharmaceuticals Inc., of Cambridge, Mass., reported third-quarter revenue totaling $26 million, including $17.4 million in net product revenue for U.S. sales of acute myeloid leukemia drug Tibsovo (ivosidenib), compared to total revenue of $15.2 million for the same period in 2018. The company posted a net loss of $106.2 million, compared to a net loss of $94.7 million a year ago. As of Sept. 30, Agios had cash, equivalents and marketable securities of $540.5 million. Its shares (NASDAQ:AGIO) closed Thursday at $30.08, down $1.54.
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported third-quarter global net product revenue totaling $46.1 million for RNAi drug Onpattro (patisiran), approved in August 2018 to treat hereditary transthyretin-mediated amyloidosis. Since launch, the company said more than 600 patients worldwide have begun treatment with Onpattro. Total revenues for the quarter were about $70 million. The company's GAAP net loss was $208.5 million, or $1.92 per share, while non-GAAP net loss was $162.5 million, or $1.50 per share. As of Sept. 30, Alnylam had about $1.74 billion on its balance sheet. Shares (NASDAQ:ALNY) closed Thursday at $86.74, down 53 cents.
Celgene Corp., of Summit, N.J., posted third-quarter revenue totaling $4.5 billion, up 16% year over year. Sales of Revlimid (lenalidomide) were $2.77 billion, up 13% year over year, while sales of Pomalyst/Imnovid (pomalidomide) jumped 29% to $664 million. Abraxane (nab-paclitaxel) sales totaled $318 million, up 10% year over year. Sales of oral psoriasis drug Otezla (apremilast) reached $547 million for the quarter, up 27% over the same period last year. Celgene agreed in August to sell Otezla to Thousand Oaks, Calif.-based Amgen Inc. to satisfy the FTC ahead of Celgene's proposed acquisition by Bristol-Myers Squibb Co., of New York, set to close by year-end. Celgene's third-quarter net income was $1.691 billion, or $2.32 per share, compared to $1.082 billion, or $1.50 per share, for the same period in 2018. The firm ended the third quarter with about $10.9 billion in cash, equivalents, marketable debt securities and publicly traded equity securities. Its shares (NASDAQ:CELG) closed Thursday at $108.03, up 86 cents. (See BioWorld, Aug. 27, 2019.)
Ironwood Pharmaceuticals Inc., of Boston, reported total revenue of $131 million for the third quarter, driven primarily by sales revenue from constipation drug Linzess (linaclotide). The company said Linzess prescriptions grew 15% year over year. Partner Allergan plc, of Dublin, reported total Linzess U.S. net sales of $214.7 million, up 5% over the third quarter of 2018. GAAP net income totaled $20.6 million, or 13 cents per share, while non-GAAP net income was $62.9 million, or 40 cents per share. Ironwood ended the third quarter with $133.2 million in cash and equivalents. Shares of Ironwood (NASDAQ:IRWD) closed Thursday at $10.04, up 61 cents.
Swedish Orphan Biovitrum AB, of Stockholm, reported revenue growth of 27% year over year, totaling SEK2.93 billion (US$304.3 million) for the third quarter. Sales of hemophilia drugs Elocta (antihemophilic factor [recombinant], Fc fusion protein) and Alprolix (coagulation factor IX [recombinant], Fc fusion protein) totaled SEK1.156 billion and SEK341 million, respectively, for the quarter. Sales of Gamifant (emapalumab), a drug indicated for rare disease primary hemophagocytic lymphohistiocytosis, reached SEK67 million, while sales of respiratory syncytial virus drug Synagis (palivizumab) totaled SEK124 million and sales of Kineret (anakinra), which Sobi has expanded into pediatric autoinflammatory diseases, reached SEK409 million. Sobi posted third-quarter earnings per share of SEK1.099 billion, up 18% over the prior year. The company ended the quarter by announcing its plan to buy Dova Pharmaceuticals Inc., a small rare disease company based in Durham, N.C., in a deal valued at about $915 million. Shares of Sobi (Stockholm:SOBI) closed Thursday at SEK152.90. (See BioWorld, Oct. 1, 2019.)
Vertex Pharmaceuticals Inc., of Boston, reported product revenues totaling $950 million for the third quarter, up 21% year over year. Sales of cystic fibrosis (CF) drugs Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor) totaled $249 million, $297 million and $404 million, respectively, for the quarter. Vertex expanded its commercial CF portfolio earlier this month, with FDA approval of triple-combination Trikafta (elexacaftor/ivacaftor/tezacaftor) targeting a mutation estimated to affect 90% of the CF population. Vertex posted GAAP income of $58 million, or 22 cents per share, for the third quarter. Non-GAAP net income was $322 million, or $1.23 per share. As of Sept. 30, Vertex had about $4 billion in cash, equivalents and marketable securities. Shares of Vertex (NASDAQ:VRTX) closed Thursday at $195.48, down $3.80.